165 related articles for article (PubMed ID: 38264853)
21. Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ.
McElree IM; Mott SL; Hougen HY; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jul; 42(7):221.e9-221.e16. PubMed ID: 38609747
[TBL] [Abstract][Full Text] [Related]
22. Sequential Intravesical Chemotherapy for Treatment Naïve, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls.
Refugia JM; Roebuck E; Thakker P; Sandberg M; Needham M; Hemal AK; Tsivian M
Urology; 2024 Jun; ():. PubMed ID: 38906268
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
Daniels MJ; Barry E; Milbar N; Schoenberg M; Bivalacqua TJ; Sankin A; Kates M
Urol Oncol; 2020 Feb; 38(2):40.e17-40.e24. PubMed ID: 31473090
[TBL] [Abstract][Full Text] [Related]
25. Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
Ansari Djafari A; Javanmard B; Razzaghi M; Hojjati SA; Razzaghi Z; Faraji S; Rahavian A; Garoosi M
Urol J; 2023 Feb; 20(2):123-128. PubMed ID: 35689462
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
27. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
28. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin-Unresponsive and Bacillus Calmette-Guérin-Exposed Nonmuscle-Invasive Bladder Cancer.
Abou Chakra M; Shore ND; Dillon R; O'Donnell MA
Urol Pract; 2024 Jan; 11(1):97-107. PubMed ID: 37903746
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
Akbulut F; Pazir Y; Esmeray A; Erbin A; Ozgor F; Sarilar O
Urologia; 2023 Nov; 90(4):631-635. PubMed ID: 37470319
[TBL] [Abstract][Full Text] [Related]
30. A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
Patel SH; Gabrielson AT; Chan S; Schwartz D; Collins C; Singla N; Trock B; Bivalacqua TJ; Hahn N; Kates MR
J Urol; 2024 Jul; 212(1):95-103. PubMed ID: 38653234
[TBL] [Abstract][Full Text] [Related]
31. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
Kawada T; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Chlosta M; Pradere B; Teoh JY; Babjuk M; Araki M; Shariat SF
Urol Oncol; 2023 Jun; 41(6):261-273. PubMed ID: 37137745
[TBL] [Abstract][Full Text] [Related]
33. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
[TBL] [Abstract][Full Text] [Related]
34. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
Guerrero-Ramos F; González-Padilla DA; González-Díaz A; de la Rosa-Kehrmann F; Rodríguez-Antolín A; Inman BA; Villacampa-Aubá F
World J Urol; 2022 Apr; 40(4):999-1004. PubMed ID: 35037963
[TBL] [Abstract][Full Text] [Related]
35. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF; Tran B; Rouprêt M; Gschwend JE; Loriot Y; Nishiyama H; Redorta JP; Daneshmand S; Hussain SA; Cutuli HJ; Procopio G; Guadalupi V; Vasdev N; Naini V; Crow L; Triantos S; Baig M; Steinberg G;
Ann Oncol; 2024 Jan; 35(1):98-106. PubMed ID: 37871701
[TBL] [Abstract][Full Text] [Related]
36. Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
Kavoussi M; Nasrallah AA; Williams SB
Eur Urol; 2022 Dec; 82(6):659. PubMed ID: 36089530
[No Abstract] [Full Text] [Related]
37. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
JAMA Netw Open; 2023 Feb; 6(2):e230849. PubMed ID: 36853609
[TBL] [Abstract][Full Text] [Related]
38. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
39. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
40. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]